<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">312</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2020-19-1-100-107</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL SIGNIFICANCE OF BASIC RESEARCH</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ФУНДАМЕНТАЛЬНЫХ ИССЛЕДОВАНИЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Specific features of intracellular calcium signalling, distinctive for Wiskott-Aldrich syndrome patients</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности внутриклеточной кальциевой сигнализации тромбоцитов при синдроме Вискотта–Олдрича</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0211-6325</contrib-id><name-alternatives><name xml:lang="en"><surname>Martyanov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Мартьянов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1443-4902</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozova</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Морозова</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7684-9188</contrib-id><name-alternatives><name xml:lang="en"><surname>Khoreva</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Хорева</surname><given-names>А. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8128-7757</contrib-id><name-alternatives><name xml:lang="en"><surname>Panteleev</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Пантелеев</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, DSc, Head of the Laboratory of cellular hemostasis and trombosis,</p><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>д-р физ.-мат. наук, профессор, зав. лабораторией клеточного гемостаза и тромбоза,</p><p>117997, Москва, ГСП-7, ул. Саморы Машела, 1</p></bio><email>mapanteleev@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3113-4939</contrib-id><name-alternatives><name xml:lang="en"><surname>Shcherbina</surname><given-names>A. Yu.</given-names></name><name xml:lang="ru"><surname>Щербина</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4720-7319</contrib-id><name-alternatives><name xml:lang="en"><surname>Sveshnikova</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Свешникова</surname><given-names>А. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Centre for Theoretical Problems of Physico-Chemical Pharmacology Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Institute for Biochemical Physics, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» РАН</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Moscow Institute of Physics and Technology</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский физико-технический институт»</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-03-28" publication-format="electronic"><day>28</day><month>03</month><year>2020</year></pub-date><volume>19</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>100</fpage><lpage>107</lpage><history><date date-type="received" iso-8601-date="2020-03-28"><day>28</day><month>03</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-03-28"><day>28</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/312">https://hemoncim.com/jour/article/view/312</self-uri><abstract xml:lang="en"><p>Wiskott–Aldrich syndrome (WAS) is a rare X-linked immunodeficient disease accompanied by microthrombocytopenia, which leads to spontaneous/post-traumatic haemorrhages. It has been demonstrated that WAS is caused by gene mutation of WASP protein, which is participating in the processes of actin polarization and actin cytoskeleton re-organisation. It is yet unknown how this mutation affects intracellular signalling and functional responses of platelets of patients with WAS. Assessment of the intracellular calcium signalling, shape change and fibrinogen binging by the platelets of WAS patients. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. Three patients with WAS and three healthy volunteers were included in the study. Intracellular signaling and platelet functional responses were observed on a BD Facs Canto II flow cytometer. To measure the calcium concentration in the platelet cytosol, the Fura-Red fluorophore was used, platelet shape change upon activation was evaluated by side scattering of cells at a wavelength of 488 nm, platelet integrin activation was evaluated by binding of fluorescently-labeled fibrinogen. During activation, the platelet concentration was 1000 cells per ul to avoid the effects of secondary activation. In quescent state of platelets, an increased concentration of calcium in the cytosol of platelets of patients was observed compared with platelets of healthy donors. In response to stimulation, the highest achievable calcium concentrations were comparable in both cases. The binding of fibrinogen to platelets in patients was not significantly changed compared to healthy donors. On the other hand, the change in the shape of the cells in response to activation, expressed as a percentage, was more significant in patients than the change in the shape of the platelets of healthy donors. With similar maximum responses to stimulation by all agonists, the concentration of calcium in resting platelets, as well as the change in the platelet shape of patients with WAS is significantly higher than that of healthy platelet donors. These results can be explained by the increased ratio of the platelet membrane area to their volume.</p></abstract><trans-abstract xml:lang="ru"><p>Одна из ключевых особенностей синдрома Вискотта–Олдрича (СВО), редкого X-сцепленного иммунодефицитного состояния, – микротромбоцитопения, приводящая к спонтанным/посттравматическим кровотечениям. Причиной развития синдрома Вискотта–Олдрича является мутация в гене белка WASP, участвующего в поляризации актина и перестройке актинового цитоскелета. Механизм влияния данной мутации на внутриклеточную кальциевую сигнализацию, а также функциональные ответы тромбоцитов пациентов с СВО не уточнены. Цель исследования: анализ кальциевой сигнализации, изменения формы и связывания фибриногена тромбоцитами пациентов с СВО. Данное исследование поддержано Независимым этическим комитетом и утверждено решением Ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева Минздрава России. В исследование были включены 3 пациента с СВО и 3 здоровых добровольца. Внутриклеточная сигнализация и функциональные ответы тромбоцитов наблюдались на проточном цитометре BD Facs Canto II. Для измерения концентрации кальция в цитозоле тромбоцитов использовали флуорофор Fura-Red; изменение формы тромбоцитов при активации оценивали по боковому светорассеянию клеток на длине волны 488 нм; активацию тромбоцитарных интегринов – по связыванию флуоресцентно-меченного фибриногена. Во время активации концентрация тромбоцитов составляла 1000 клеток/мкл во избежание эффекта вторичной активации. В покоящемся состоянии тромбоцитов наблюдалась повышенная концентрация кальция в цитозоле тромбоцитов пациентов по сравнению с тромбоцитами здоровых доноров. В ответ на стимуляцию максимально достижимые концентрации кальция были сопоставимы в обоих случаях. Связывание фибриногена с тромбоцитами пациентов не было значимо изменено по сравнению со здоровыми донорами. С другой стороны, изменение формы клеток в ответ на активацию, выраженное в процентах, у пациентов оказалось более значимым, чем изменение формы тромбоцитов здоровых доноров. При схожих максимальных ответах на стимуляцию всеми агонистами концентрация кальция в покоящихся тромбоцитах, а также изменение формы тромбоцитов у пациентов с СВО значимо выше, чем у тромбоцитов здоровых доноров. Данные результаты можно объяснить увеличенным отношением площади мембраны тромбоцитов к их объему.</p></trans-abstract><kwd-group xml:lang="en"><kwd>platelets</kwd><kwd>Wiskott–Aldrich Syndrome</kwd><kwd>calcium signalling</kwd><kwd>flow cytometry</kwd><kwd>orphan disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тромбоциты</kwd><kwd>синдром Вискотта–Олдрича</kwd><kwd>кальциевая сигнализация</kwd><kwd>проточная цитометрия</kwd><kwd>орфанные заболевания</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа была поддержана стипендией Президента РФ СП-2675.2019.4, грантом Фонда поддержки и развития в области детской гематологии, онкологии и иммунологии «Наука – детям», грантами РФФИ 17-00-00141 (17-00-00140/17-00-00138) и 18-34-20026.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Candotti F. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott–Aldrich Syndrome. J Clin Immunol 2018; 38 (1): 13–27.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Perry G.S. 3rd, Spector B.D., Schuman L.M., Mandel J.S., Anderson V.E., McHugh R.B., et al. The Wiskott–Aldrich syndrome in the United States and Canada (1892- 1979). J Pediatr 1980; 97: 72–8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Moratto D., Giliani S., Notarangelo L.D., Mazza C., Mazzolari E., Notarangelo L.D. The Wiskott–Aldrich syndrome: from genotype–phenotype correlation to treatment. Expert Rev. Clin Immunol 2007; 3: 813–24.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Rivers E., Thrasher A.J. Wiskott–Aldrich syndrome protein: Emerging mechanisms in immunity. Eur J Immunol 2017; 47: 1857–66.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Taylor M.D., Sadhukhan S., Kottangada P., Ramgopal A., Sarkar K., D’Silva S., et al. Nuclear Role of WASp in the Pathogenesis of Dysregulated TH1 Immunity in Human Wiskott–Aldrich Syndrome. Sci Transl Med 2010; 2: 37ra44 LP-37ra44.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Patel P.D., Samanich J.M., Mitchell W.B., Manwani D. A unique presentation of Wiskott–Aldrich syndrome in relation to platelet size. Pediatr. Blood Cancer 2011; 56: 1127–9.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ochs H.D., Slichter S.J., Harker L.A., Von Behrens W.E., Clark R.A., Wedgwood R.J. The Wiskott–Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 1980; 55: 243–52.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Haddad E., Cramer E., Riviere C., Rameau P., Louache F., Guichard J., et al. The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood 1999; 94: 509–18.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Prislovsky A., Zeng X., Sokolic R.A., Garabedian E.N., Anur P., Candotti F., Strom T.S. Platelets from WAS patients show an increased susceptibility to ex vivo phagocytosis. Platelets 2013; 24: 288–96.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Shcherbina A., Rosen F.S., Remold-O’Donnell E. Pathological events in platelets of Wiskott–Aldrich syndrome patients. Br J Haematol 1999; 106: 875–83.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mahlaoui N., Pellier I., Mignot C., Jais J.-P., Bilhou-Nabera C., Moshous D., et al. Characteristics and outcome of early-onset, severe forms of Wiskott–Aldrich syndrome. Blood 2013; 121: 1510–6.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Sandrock K., Zieger B. Current Strategies in Diagnosis of Inherited Storage Pool Defects. Transfus Med Hemother 2010; 37: 248–58.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ignatova A.A., Ponomarenko E.A., Polokhov D.M., Suntsova E.V., Zharkov P.A., Fedorova D.V., et al. Flow cytometry for pediatric platelets. Platelets 2019; 30 (4): 428–37.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Obydennyi S.I., Artemenko E.O., Sveshnikova A.N., Ignatova A.A., Varlamova T.V., Gambaryan S., et al. Mechanisms of increased mitochondria-dependent necrosis in Wiskott–Aldrich syndrome platelets. Haematologica 2019. DOI: 10.3324/haematol.2018.214460 [Epub ahead of print].</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Medina S.S., Siqueira L.H., Colella M.P., Yamaguti-Hayakawa G.G., Duarte B.K.L., Dos Santos Vilela M.M., Ozelo M.C. Intermittent low platelet counts hampering diagnosis of X-linked thrombocytopenia in children: report of two unrelated cases and a novel mutation in the gene coding for the Wiskott–Aldrich syndrome protein. BMC Pediatr 2017; 17: 151.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sokolic R., Oden N., Candotti F. Assessment of Immature Platelet Fraction in the Diagnosis of Wiskott–Aldrich Syndrome. Front Pediatr 2015; 3: 49.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Obydennyy S.I., Sveshnikova A.N., Ataullakhanov F.I., Panteleev M.A. Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. J Thromb Haemost 2016; 14: 1867–81.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fischer A. Platelets are the Achilles’ heel of Wiskott–Aldrich syndrome. J Allergy Clin Immunol 2019; 144: 668–70.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kwan A., Abraham R.S., Currier R., Brower A., Andruszewski K., Abbott J.K., et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312: 729–38.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chiang S. Screening for Wiskott–Aldrich syndrome by flow cytometry. J Allergy Clin Immunol 2018; 142: 333–5.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Sveshnikova A.N., Balatskiy A.V., Demianova A.S., Shepelyuk T.O., Shakhidzhanov S.S., Balatskaya M.N., et al. Systems biology insights into the meaning of the platelet’s dual-receptor thrombin signaling. J Thromb Haemost 2016; 14: 2045–57.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440–50.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Schoenmakers T.J., Visser G.J., Flik G., Theuvenet A.P. CHELATOR: an improved method for computing metal ion concentrations in physiological solutions. Biotechniques 1992; 12: 870–9.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Heemskerk J.W.M., Hoyland J., Masont W.T., Sage S. Spiking in cytosolic calcium concentration in single fibrinogen-bound fura-2-loaded human platelets. Biochem J 1992; 283: 379–83.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Poulter N.S., Pollitt A.Y., Davies A., Malinova D., Nash G.B., Hannon M.J., et al. Platelet actin nodules are podosome-like structures dependent on Wiskott-Aldrich syndrome protein and ARP2/3 complex. Nat Commun 2015; 6: 7254.</mixed-citation></ref></ref-list></back></article>
